# INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

> **NCT03502785** · PHASE1,PHASE2 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** INO-5401
- **BIOLOGICAL:** INO-9012
- **DRUG:** Atezolizumab
- **DEVICE:** CELLECTRA™ 2000

## Key facts

- **NCT ID:** NCT03502785
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-24
- **Primary completion:** 2025-05-09
- **Final completion:** 2025-05-09
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03502785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03502785, "INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03502785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*